The DNA Company’s Liquid B (Liquid Biopsy) is a minimally invasive and highly accurate cancer screening tool. Through a unique partnership between The DNA Company and QuantGene, this next-generation sequencing technology is a breakthrough in the early detection and possible discovery of cancer.  Through genetic analysis of blood for cancer signals, The DNA Company’s Liquid B can provide awareness around irregularities.  These results can provide your healthcare professional with a powerful tool for detection and potential treatment suggestions.  

Our Liquid B delivers a personalized and detailed reports on risk factors, preventative measures, and identifies early signals of up to 16 distinct types of cancer. This comprehensive report integrates high-resolution sequencing data with clinical insights, offering a comprehensive overview.  

Liquid B requires a blood sample to be collected for screening. The Concierge Team will schedule an at-home appointment with your phlebotomist. Once the sample is run and the test performed, you will receive your comprehensive report and a consultation with a clinician for review and discussion of your potential next steps.  

Take a proactive approach to comprehensive cancer screening with The DNA Company’s Liquid B. 

**Please Note: Due to local laws and regulations, we currently DO NOT offer our Liquid B Test outside the US, and DO NOT service New York, New Jersey and Rhode Island at this time.